{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-029050","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2024-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.852961+00:00","generated_at":"2026-06-01T05:57:24.668997+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BridgeBio reports positive Phase 2 infigratinib results in achondroplasia; initiates hypochondroplasia study","bullets":["Cohort 5 (0.25 mg/kg/day) showed sustained AHV increase: +2.51 cm/yr at Month 12, +2.50 cm/yr at Month 18 (p=0.0015).","Statistically significant improvement in body proportionality: upper/lower segment ratio 1.88 at Month 18 vs 2.02 baseline (p=0.001).","No treatment-related adverse events in Cohort 5; drug well-tolerated as single daily oral therapy.","First child consented in ACCEL observational study for hypochondroplasia; Phase 2/3 interventional study planned.","PROPEL 3 Phase 3 registrational enrollment on schedule, completion estimated by end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-029050","json":"https://secwatch.observer/filing/0001140361-24-029050.json","markdown":"https://secwatch.observer/filing/0001140361-24-029050.md","text":"https://secwatch.observer/filing/0001140361-24-029050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000114036124029050/0001140361-24-029050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000114036124029050/ef20030678_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:57:24.668997+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}